Syndicated Reports
Reimbursement IQ Syndicated Reports: Payer Responses to Development-Stage Products in Key Therapeutic Areas
Each year, we survey payers on their evolving thinking about the latest scientific developments in key therapeutic areas in order to understand how they’re likely to respond with access and cost controls to the newest therapies from the biopharma companies. In general, we deliver these reports after new clinical-trial data is released at national meetings including American Society of Clinicial Oncologists (ASCO), American Society of Hematology (ASH), American College of Rheumatology (ACR), American Academy of Neurology (AAN), Interscience Conference on Antimicrobial Agents (ICAAC) and Digestive Diseases Week (DDW). These reports give our clients a detailed understanding of likely formulary placement, response to clinical trial endpoints, pricing and impact on current treatment pathways.
At each national meeting, we identify 15 compounds in development that payers and pharmaceutical companies identified as innovative and potentially game changing in treatment. Our analysts review the clinical data and also compile what payers “want to know” about these pipeline products or new trial data or indication for in line products.
Our report surveys 50 of the most influential national and regional plans immediately after the meeting to gauge their responses, using our RIN to identify plan respondents with primary responsibility for formulary decision making and/or pricing and contracting.
Each report is divided into two broad sections – payer strategies in the therapeutic category overall, and specific reimbursement discussions of emerging therapies.
Every year our Report changes with the forces in the market place and includes research that focuses on issues and trends relevant to the therapeutic category that may include:
- How will different plans develop and use comparative effectiveness?
- How do payers plan to use accountable care organizations to manage treatment and pharmacy costs?
- How will plans employ biomarkers and gene selectivity in product selection?
In addition, we can customize the reports. Clients can add their own proprietary questions to our surveys – for example, specifically asking about their own clinical-trial results or endpoints or those of their competitors. Furthermore, Reimbursement Intelligence can provide additional data analysis to allow clients to get deeper insight by doing more significant segmentation – by focusing, for example, on the class of payer (e.g., Medicare vs. commercial) or the kind of managed-care executive (e.g., medical vs. pharmacy directors).
Our RIQ reports are the most cost effective option for pharmaceutical companies seeking payer responses to the latest reimbursement thinking about the industry’s newest and best innovations.
Recent RIQ reports include:
Oncology Reimbursement Report 2011-2012
An in-depth assessment of how 55 health plans, covering more than 150 million lives in Commercial, Medicare and Medicaid segments are currently responding, and will respond in the future, to cancer therapies in general and to specific marketed and pipeline products in lung, breast, melanoma and hematologic cancers.
Alzheimer’s 2011-2012: Insights on Emerging Therapies from Providers and Payers
A Landmark Study from the Alzheimer’s Drug Discovery Foundation and Reimbursement Intelligence.
Alzheimer’s: No disease more devastating – more costly – more important to treat.
And for companies with Alzheimer’s therapies in development, no disease poses a more complicated commercial problem in part because physicians and payers are on very different pages about the value of current and emerging therapies.
Alzheimer’s 2011-2012 – a collaboration between The Alzheimer’s Drug Discovery Foundation and Reimbursement Intelligence – delivers an action-oriented understanding of the evolving Alzheimer’s reimbursement world with data from a comprehensive survey of 100 physicians (neurologists, geriatricians and PCPs) as well as 50 formulary decision makers from top commercial and Medicare plans.
It provides the tools successful companies will need to…
- Build an effective health outcomes research plan that clearly shows skeptical payers the value of your new therapy;
- Design reimbursement plans that meet both physician and payer needs;
- Create the right managed-markets launch plan using a clear map of current formulary placement, reimbursement, and utilization restrictions;
- Forecast revenues accurately using the report’s pricing intelligence;
- Target the right messages to physicians with feedback on their patient selection, use of new therapies, and clinical expectations…
COMING SOON
Rheumatology Reimbursement Report 2011-2012
Ask any senior pharmacy or medical director which therapeutic category he or she is most worried about – and more often than not you’ll hear “rheumatology”. It is also a hotbed of reimbursement experimentation, with many managed care groups looking at new access models for the current slate of products – and for those in development. Using the newest clinical data from the annual conference of the American College of Rheumatology in November, we’ll be grilling our managed care network for the reimbursement so-what’s when it comes to rheumatoid arthritis, lupus, osteoporosis, and psoriatic arthritis.
For more information on any of our market research programs, please contact Mark Flanick at mflanick@reimbursementintelligence.com or 973 805 2302.